Education
About Us
Working with TipRanks
Follow Us
Retractable Technologies (RVP)
:RVP
RESEARCH TOOLSreports
Top Page
Retractable Technologies
(NYSE MKT:RVP)
55Neutral
Retractable Technologies (RVP) vs. S&P 500 (SPY)
Market Cap
$21.55M
Dividend YieldN/A
Average Volume (3M)49.80K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth-8.86%
EPS Growth-39.37%
CountryUS
Employees151
SectorHealthcare
Sector Strength78
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-0.53
Shares Outstanding29,937,159
10 Day Avg. Volume44,773
30 Day Avg. Volume49,802
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.56
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Retractable Technologies Business Overview & Revenue Model
Company DescriptionRetractable Technologies, Inc. (RVP) is a medical device company specializing in the design, manufacture, and marketing of safety medical products. The company's core products include retractable syringes, blood collection devices, and IV catheters, all designed to reduce the risk of needlestick injuries and prevent cross-contamination. With a focus on innovative safety solutions, Retractable Technologies operates in the healthcare sector, supplying its products to hospitals, clinics, and other healthcare facilities globally.
How the Company Makes MoneyRetractable Technologies generates revenue primarily through the sale of its safety medical products to healthcare providers, distributors, and government agencies. The company's income is largely dependent on the demand for its retractable syringe technology, which offers a safer alternative to traditional syringes. Additionally, Retractable Technologies benefits from long-term contracts and partnerships with healthcare organizations and governmental health departments seeking to enhance safety protocols. The company may also receive income from licensing agreements or partnerships with other medical device manufacturers interested in incorporating its safety technology into their product lines.
Retractable Technologies Financial Statement Overview
Summary
Retractable Technologies is facing financial difficulties with declining revenues and negative net income, indicating operational inefficiencies. The balance sheet's low debt-to-equity ratio shows limited debt reliance, but liquidity is pressured by negative cash flows.Income Statement
Retractable Technologies has faced significant challenges with declining revenues and profitability. The TTM data shows a notable decrease in total revenue and a negative net income, indicating operational difficulties. Gross profit margins have significantly contracted from previous years, and both EBIT and net profit margins are negative, pointing to inefficiencies in managing costs and expenses.45
Neutral
Balance Sheet
The company's balance sheet reflects a relatively conservative financial structure with a low debt-to-equity ratio, suggesting limited reliance on external debt. However, stockholders' equity has decreased, reflecting potential pressures on asset valuation and profitability. The equity ratio remains stable, indicating a solid portion of assets financed by equity.58
Neutral
Cash Flow
Cash flow analysis reveals a concerning trend with negative operating and free cash flows in the TTM, highlighting liquidity pressures. The operating cash flow to net income ratio is negative, suggesting challenges in converting profits into cash. Historical free cash flow growth has been volatile, indicating inconsistency in cash generation capabilities.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 38.27M | 43.60M | 94.82M | 188.38M | 81.86M | 41.80M | Gross Profit |
| 3.01M | 9.11M | 28.25M | 95.35M | 37.01M | 14.14M | EBIT |
| -16.66M | -11.49M | 2.99M | 72.60M | 24.07M | 2.97M | EBITDA |
| 178.62K | -1.24M | 9.94M | 76.44M | 27.17M | 4.18M | Net Income Common Stockholders |
| -15.73M | -7.01M | 5.08M | 56.06M | 24.22M | 3.15M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 10.64M | 47.29M | 49.38M | 42.43M | 25.65M | 13.71M | Total Assets |
| 36.79M | 179.67M | 195.67M | 206.30M | 104.97M | 39.18M | Total Debt |
| 3.05M | 1.54M | 1.82M | 2.10M | 3.74M | 2.64M | Net Debt |
| -6.60M | -11.13M | -17.90M | -27.06M | -13.83M | -3.30M | Total Liabilities |
| 11.18M | 80.38M | 89.13M | 107.14M | 55.09M | 10.64M | Stockholders Equity |
| 25.61M | 99.29M | 106.54M | 99.17M | 49.88M | 28.54M |
| Cash Flow | Free Cash Flow | ||||
| -9.85M | 1.91M | -61.95K | -25.57M | -2.05M | 1.56M | Operating Cash Flow |
| -8.56M | 2.77M | 16.77M | 32.79M | 19.00M | 2.19M | Investing Cash Flow |
| 1.75M | -10.76M | -31.20M | -63.04M | -19.33M | -5.28M | Financing Cash Flow |
| -534.79K | 941.64K | 4.99M | 41.84M | 11.96M | -626.84K |
Retractable Technologies Technical Analysis
Negative
0.74
Price Trends
0.78
Negative
0.73
Positive
0.86
Negative
Market Momentum
-0.01
Positive
43.12
Neutral
26.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.78, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.12 is Neutral, neither overbought nor oversold. The STOCH value of 26.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVP.
Retractable Technologies Risk Analysis
Retractable Technologies disclosed 17 risk factors in its most recent earnings report. Retractable Technologies reported the most risks in the “Macro & Political” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Retractable Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $17.23B | 42.39 | 43.03% | ― | 22.07% | 101.95% | |
73 Outperform | $65.31B | 38.13 | 6.92% | 1.73% | 5.89% | 42.05% | |
56 Neutral | $1.19B | ― | -33.30% | ― | 25.74% | 57.18% | |
55 Neutral | $21.55M | ― | -17.20% | ― | -8.86% | -39.37% | |
53 Neutral | $3.41B | ― | -5.76% | ― | 5.28% | -292.14% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
46 Neutral | $2.52B | ― | -50.74% | ― | -7.03% | -20233.78% |
* Healthcare Sector Average
Performance Comparison
RVP
Retractable Technologies
0.74
-0.48
-39.34%
BDX
Becton Dickinson
223.82
-10.88
-4.64%
ICUI
ICU Medical
141.59
40.35
39.86%
PODD
Insulet
248.38
72.84
41.49%
QDEL
QuidelOrtho
36.87
-10.39
-21.98%
TNDM
Tandem Diabetes Care
18.77
-9.86
-34.44%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.